Cytokinetics Announces Proposed Public Offering of Common Stock

Group 1 - Cytokinetics plans to offer approximately $500 million of its common stock in an underwritten public offering, subject to market conditions [1] - The company expects to grant underwriters a 30-day option to purchase up to an additional 15% of the shares sold in the offering [1] - All shares in the offering will be sold by Cytokinetics [1] Group 2 - J.P. Morgan, Goldman Sachs & Co. LLC, and Morgan Stanley are acting as sole joint book-running managers for the offering [2] - The offering is being conducted under a shelf registration statement filed with the SEC on November 18, 2022, which has become automatically effective [3] Group 3 - Cytokinetics is a late-stage biopharmaceutical company focused on developing muscle activators and inhibitors for diseases affecting muscle performance [5]